Prime Medicine, Inc.PRMENASDAQ
Loading
PRME Revenue Growth (YoY Quarterly)•-61.61%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
-61.61%
-547.7pp
+1703.53%
+22265.2pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+25.43%
-8.6pp
+25.43%
-8.6pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +146.02% | +0.00% | +486.12% | -61.61% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | -20561.72% | +1703.53% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +21.79% | +25.29% | +8.39% | +34.02% | +25.43% |
| Weighted Average Shares Diluted Growth | +21.79% | +25.29% | +8.39% | +34.02% | +25.43% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -329.34% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -359.76% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | -100.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +53.47% | +5.39% | +7.43% | +15.69% | +15.20% |
| Book Value per Share Growth | -5.51% | -64.99% | -71.44% | -36.28% | -37.08% |
| Debt Growth | +199.23% | +176.64% | +187.94% | +186.40% | +185.40% |
| R&D Expense Growth | -17.74% | +7.38% | -3.94% | +9.05% | +1.77% |
| SG&A Expenses Growth | -5.98% | +19.05% | +4.09% | -20.52% | +19.80% |
1 / 4